Short answer
Personalis, Inc. (PSNL) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $15M (down 24.9% year over year) with net income of −$30M.
Q1 2026 key financials · XBRL
- Revenue
- $15M
- −24.9% YoY
- Net income
- −$30M
- −90.7% YoY
- Operating margin
- -207.9%
- EPS (diluted)
- −$0.29
- −61.1% YoY
Source: XBRL data from the Personalis, Inc. (PSNL) Q1 2026 10-Q on SEC EDGAR. USD.
Personalis, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $15.5M, down 25% YoY from $20.6M
- Clinical diagnostic revenue $1.4M, up 365% YoY from $0.3M
- Enterprise sales $0.4M, down 84% YoY from $2.5M
- Net loss $30.0M versus $15.8M; operating margin -207.9% versus -85.9% YoY
- Cash and short-term investments $233.2M versus $240.0M at December 31, 2025
Risk Factors
- Net loss $30.0M in Q1 2026 and accumulated deficit $661.0M, with continued losses expected
- Merck represented 19% of Q1 2026 revenue, increasing customer concentration risk
- Top five customers accounted for 69% of Q1 2026 revenue, exposing results to contract reductions or cancellations
- VA MVP fourth task order valued up to $13.5M, with future renewals discretionary
- Natera relationship became immaterial after minimum volume commitments expired following Q2 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Personalis, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.